$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd

$irwd Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000155837022001368 Filed on February 18, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021
Revenue	$117.1M	$103.7M	$413.8M
YoY Change	0.39%	0.27%	6.22%
Cost Of Revenue	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Gross Profit	$117.1M	$103.7M	$413.8M
YoY Change	1.15%	0.24%	7.08%
Gross Profit Margin	100.0%	100.0%	100.0%
Selling, General & Admin	$28.69M	$27.74M	$111.1M
YoY Change	-19.87%	-20.57%	-20.62%
% of Gross Profit	24.49%	26.74%	26.86%
Research & Development	$31.85M	$10.91M	$70.41M
YoY Change	95.4%	-49.72%	-20.05%
% of Gross Profit	27.19%	10.51%	17.02%
Depreciation & Amortization	$359.0K	$358.0K	$1.500M
YoY Change	-28.2%	-80.11%	-34.78%
% of Gross Profit	0.31%	0.35%	0.36%
Operating Expenses	$60.54M	$38.65M	$181.5M
YoY Change	16.42%	-31.74%	-20.4%
Operating Profit	$56.59M	$65.17M	$232.3M
YoY Change	-11.3%	42.87%	62.49%
Interest Expense	-$10.34M	$7.841M	$31.15M
YoY Change	49.81%	5.69%	5.67%
% of Operating Profit	-18.27%	12.03%	13.41%
Other Income/Expense, Net	-$10.34M	-$5.499M	-$31.60M
YoY Change	50.16%	-43.91%	-7.27%
Pretax Income	$46.26M	$59.67M	$200.7M
YoY Change	3.94%	66.63%	84.32%
Income Tax	$4.881M	$3.800M	-$327.8M
% Of Pretax Income	10.55%	6.37%	-163.36%
Net Earnings	$41.37M	$55.85M	$528.4M
YoY Change	-4.24%	62.23%	397.71%
Net Earnings / Revenue	35.32%	53.83%	127.72%
Basic Earnings Per Share	$0.25	$0.34	$3.26
Diluted Earnings Per Share	$0.25	$0.34	$3.21
COMMON SHARES
Basic Shares Outstanding	163.7M	162.7M	162.2M
Diluted Shares Outstanding		165.2M	164.4M

Balance Sheet

Concept	2021 Q4	2021 Q3	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$620.1M	$574.3M	$620.1M
YoY Change	71.02%	86.7%	71.02%
Cash & Equivalents	$620.1M	$574.3M	$620.1M
Short-Term Investments
Other Short-Term Assets	$11.05M	$19.33M	$11.05M
YoY Change	1.41%	54.6%	1.41%
Inventory
Prepaid Expenses
Receivables	$114.0M	$101.8M	$114.0M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$745.2M	$695.4M	$745.2M
YoY Change	50.3%	60.48%	50.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.575M	$7.912M	$22.93M
YoY Change	-15.16%	-15.14%	-10.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.000M	$855.0K	$334.8M
YoY Change	6.04%	-2.95%	2208.82%
Total Long-Term Assets	$381.7M	$384.0M	$381.7M
YoY Change	502.06%	550.77%	502.05%
TOTAL ASSETS
Total Short-Term Assets	$745.2M	$695.4M	$745.2M
Total Long-Term Assets	$381.7M	$384.0M	$381.7M
Total Assets	$1.127B	$1.079B	$1.127B
YoY Change	101.51%	119.24%	101.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$935.0K	$414.0K	$935.0K
YoY Change	41.45%	-79.01%	33.57%
Accrued Expenses	$42.59M	$24.96M	$42.59M
YoY Change	35.2%	-11.81%	35.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$116.9M	$120.7M	$116.9M
YoY Change
Total Short-Term Liabilities	$161.7M	$145.7M	$161.7M
YoY Change	402.59%	342.83%	402.17%
LONG-TERM LIABILITIES
Long-Term Debt	$337.3M	$333.2M	$337.3M
YoY Change	-21.61%	-21.5%	-21.61%
Other Long-Term Liabilities	$3.501M	$1.594M	$21.99M
YoY Change	98.58%	207.72%	-35.72%
Total Long-Term Liabilities	$3.501M	$1.594M	$359.3M
YoY Change	98.58%	207.72%	-22.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$161.7M	$145.7M	$161.7M
Total Long-Term Liabilities	$3.501M	$1.594M	$359.3M
Total Liabilities	$165.2M	$147.3M	$521.0M
YoY Change	386.8%	340.73%	4.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$937.6M	-$979.0M
YoY Change	-36.05%	-35.13%
Common Stock	$1.544B	$1.559B
YoY Change	0.97%	2.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$605.9M	$579.9M	$605.9M
YoY Change
Total Liabilities & Shareholders Equity	$1.127B	$1.079B	$1.127B
YoY Change	101.51%	119.24%	101.52%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021
OPERATING ACTIVITIES
Net Income	$41.37M	$55.85M	$528.4M
YoY Change	-4.24%	62.23%	397.71%
Depreciation, Depletion And Amortization	$359.0K	$358.0K	$1.500M
YoY Change	-28.2%	-80.11%	-34.78%
Cash From Operating Activities	$64.57M	$75.07M	$261.9M
YoY Change	25.37%	40.05%	55.12%
INVESTING ACTIVITIES
Capital Expenditures	-$128.0K	-$137.0K	$265.0K
YoY Change			-85.61%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change
Cash From Investing Activities	-$128.0K	-$137.0K	-$265.0K
YoY Change			-85.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$24.13M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-18.59M	6.164M	-4.550M
YoY Change	-631.06%	927.33%	-124.53%
NET CHANGE
Cash From Operating Activities	64.57M	75.07M	261.9M
Cash From Investing Activities	-128.0K	-137.0K	-265.0K
Cash From Financing Activities	-18.59M	6.164M	-4.550M
Net Change In Cash	45.85M	81.09M	257.1M
YoY Change	-16.63%	49.62%	38.56%
FREE CASH FLOW
Cash From Operating Activities	$64.57M	$75.07M	$261.9M
Capital Expenditures	-$128.0K	-$137.0K	$265.0K
Free Cash Flow	$64.70M	$75.20M	$261.6M
YoY Change	25.62%	40.3%	56.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	66687000
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	528448000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	106176000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	21505000
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.24
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	528448000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	106176000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	21505000
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	39926000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	391303000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	55845000
CY2021Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	41374000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	528448000
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3345000
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	25204000
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	34423000
CY2020Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	43204000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	106176000
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	162036461
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	160616675
CY2021Q4	us-gaap	Derivative Asset Valuation Technique Extensible List DerivativeAssetValuationTechniqueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ValuationTechniqueOptionPricingModelMember
CY2021Q4	us-gaap	Derivative Liability Valuation Technique Extensible List DerivativeLiabilityValuationTechniqueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ValuationTechniqueOptionPricingModelMember
CY2020Q4	us-gaap	Derivative Asset Valuation Technique Extensible List DerivativeAssetValuationTechniqueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ValuationTechniqueOptionPricingModelMember
CY2020Q4	us-gaap	Derivative Liability Valuation Technique Extensible List DerivativeLiabilityValuationTechniqueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ValuationTechniqueOptionPricingModelMember
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0
CY2019	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0
CY2019	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0
CY2019	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001446847
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-34620
CY2021	dei	Entity Registrant Name EntityRegistrantName	IRONWOOD PHARMACEUTICALS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3404176
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Summer Street
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2300
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02110
CY2021	dei	City Area Code CityAreaCode	617
CY2021	dei	Local Phone Number LocalPhoneNumber	621-7722
CY2021	dei	Security12b Title Security12bTitle	Class A Common Stock, $0.001 par value
CY2021	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2021	dei	Trading Symbol TradingSymbol	IRWD
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1858612775
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	159221969
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	620129000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	362564000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	114042000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	122351000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8689000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9189000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1250000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1735000
CY2021Q4	us-gaap	Hedging Assets Current HedgingAssetsCurrent	1115000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	745225000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	495839000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	485000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	485000
CY2021Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	23998000
CY2020Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	23401000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7575000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8929000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15350000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16576000
CY2020Q4	us-gaap	Hedging Assets Noncurrent HedgingAssetsNoncurrent	13065000
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	333294000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1000000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	943000
CY2021Q4	us-gaap	Assets Assets	1126927000
CY2020Q4	us-gaap	Assets Assets	559238000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	935000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	661000
CY2021Q4	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	15896000
CY2020Q4	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1898000
CY2021Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	23566000
CY2020Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	26486000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3127000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3128000
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	116858000
CY2021Q4	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	1316000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	161698000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32173000
CY2020Q4	us-gaap	Hedging Liabilities Noncurrent HedgingLiabilitiesNoncurrent	12088000
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	337333000
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	430256000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18484000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20318000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3501000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1763000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	162036461
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	160616675
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	162000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	161000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1543357000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1528535000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-937608000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1466056000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	605911000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	62640000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1126927000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	559238000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	413753000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	389523000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	428413000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3136000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23875000
CY2019	irwd	Inventory Write Down Of Net Realizable Value And Loss On Non Cancellable Purchase Commitments InventoryWriteDownOfNetRealizableValueAndLossOnNonCancellablePurchaseCommitments	-3530000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70405000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88062000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	115044000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	111133000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	140003000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	172450000
CY2019	irwd	Gain Loss On Modification Of Lease GainLossOnModificationOfLease	3169000
CY2021	irwd	Restructuring Expense Benefit RestructuringExpenseBenefit	-44000
CY2020	irwd	Restructuring Expense Benefit RestructuringExpenseBenefit	15382000
CY2019	irwd	Restructuring Expense Benefit RestructuringExpenseBenefit	3620000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	181494000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	246583000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	308290000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	232259000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	142940000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	120123000
CY2021	us-gaap	Interest Expense InterestExpense	31150000
CY2020	us-gaap	Interest Expense InterestExpense	29478000
CY2019	us-gaap	Interest Expense InterestExpense	36602000
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	726000
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	1504000
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	2862000
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-1178000
CY2020	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-6129000
CY2019	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	3023000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-30977000
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	24000
CY2019	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	514000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-31602000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-34079000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-61180000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	200657000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	108861000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	58943000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-327791000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2685000
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	528448000
CY2020	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	106176000
CY2019	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	58943000
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-37438000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	528448000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	106176000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21505000
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	3.26
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.67
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.38
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	3.21
CY2020	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.66
CY2019	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.38
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.24
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.26
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.67
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.21
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.66
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	162245000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	159427000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	156023000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	164418000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	160655000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	156023000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-196371000
CY2019	irwd	Stock Issued During Period Value Share Based Awards And Employee Stock Purchase Plan Net Of Cancellations StockIssuedDuringPeriodValueShareBasedAwardsAndEmployeeStockPurchasePlanNetOfCancellations	13601000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	-32331000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	92502000
CY2019	irwd	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Issuance Costs AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtIssuanceCosts	2092000
CY2019	irwd	Adjustments To Additional Paid In Capital Purchase Of Capped Calls AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls	25159000
CY2019	irwd	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Repurchases AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRepurchases	26959000
CY2019	us-gaap	Dividends Dividends	2609000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	21505000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-93251000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	18540000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31175000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	106176000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	62640000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	19681000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22281000
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	27139000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	528448000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	605911000
CY2021	us-gaap	Profit Loss ProfitLoss	528448000
CY2020	us-gaap	Profit Loss ProfitLoss	106176000
CY2019	us-gaap	Profit Loss ProfitLoss	21505000
CY2021	us-gaap	Depreciation Depreciation	1523000
CY2020	us-gaap	Depreciation Depreciation	3564000
CY2019	us-gaap	Depreciation Depreciation	5580000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-93000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-470000
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-146000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	22281000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	31175000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	31278000
CY2019	irwd	Gain Loss On Modification Of Lease GainLossOnModificationOfLease	3169000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10772000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-12172000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	16232000
CY2021	irwd	Fair Value Adjustment Of Convertible Note Hedging Instrument FairValueAdjustmentOfConvertibleNoteHedgingInstrument	11950000
CY2020	irwd	Fair Value Adjustment Of Convertible Note Hedging Instrument FairValueAdjustmentOfConvertibleNoteHedgingInstrument	18301000
CY2019	irwd	Fair Value Adjustment Of Convertible Note Hedging Instrument FairValueAdjustmentOfConvertibleNoteHedgingInstrument	-19255000
CY2019	irwd	Inventory Write Down Of Net Realizable Value And Loss Settlement On Non Cancellable Purchase Commitments InventoryWriteDownOfNetRealizableValueAndLossSettlementOnNonCancellablePurchaseCommitments	-3530000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	23935000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	22263000
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	19590000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-333294000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-30977000
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-7712000
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-4091000
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	68893000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-601000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1515000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1046000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-648000
CY2021	irwd	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-1226000
CY2020	irwd	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-1167000
CY2019	irwd	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-14141000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	57000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	153000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-159000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2644000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7523000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-32700000
CY2021	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	13998000
CY2020	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-1058000
CY2019	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-483000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1835000
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	218000
CY2019	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-12046000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-875000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	875000
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-1270000
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1029000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	261895000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	168836000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-639000
CY2019	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	11364000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	261895000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	168836000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10725000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	265000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1842000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7189000
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	268000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-265000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1842000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6921000
CY2019	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-4223000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-265000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1842000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11144000
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	400000000
CY2019	irwd	Purchase Of Capped Calls PurchaseOfCappedCalls	25159000
CY2019	irwd	Proceeds From Partial Termination Of Convertible Note Hedges And Note Hedge Warrants ProceedsFromPartialTerminationOfConvertibleNoteHedgesAndNoteHedgeWarrants	3174000
CY2019	irwd	Payments Of Convertible Debt Issuance Costs PaymentsOfConvertibleDebtIssuanceCosts	9048000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	19581000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18546000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13595000
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	24131000
CY2019	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	227338000
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	156409000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4550000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18546000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1185000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	257080000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	185540000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1604000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	364784000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179244000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180848000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	621864000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	364784000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179244000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	620129000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	362564000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177023000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	1735000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	2220000
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	2221000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	621864000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	364784000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179244000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	7216000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	7216000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	17584000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3452000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1848000
CY2019	us-gaap	Settlement Of Asset Retirement Obligations Through Noncash Payments Amount SettlementOfAssetRetirementObligationsThroughNoncashPaymentsAmount	486000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1282000
CY2021	irwd	Stock Repurchases Payable In Accrued Expenses StockRepurchasesPayableInAccruedExpenses	3009000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1. Nature of Business </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Ironwood Pharmaceuticals, Inc. (“Ironwood” or the “Company”) is a gastrointestinal (“GI”) healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for GI patients. The Company is focused on the development and commercialization of innovative GI product opportunities in areas of significant unmet need, leveraging its demonstrated expertise and capabilities in GI diseases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">LINZESS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="white-space:pre-wrap;"> (linaclotide), the Company’s commercial product, is the first product approved by the United States Food and Drug Administration (the “U.S. FDA”) in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”). LINZESS is available to adult men and women suffering from IBS-C or CIC in the United States (the “U.S.”) and Mexico and to adult men and women suffering from IBS-C in Japan and China. Linaclotide is available under the trademarked name CONSTELLA</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has strategic partnerships with leading pharmaceutical companies to support the development and commercialization of linaclotide throughout the world. The Company and its partner, AbbVie Inc. (together with its affiliates, “AbbVie”), began commercializing LINZESS in the U.S. in December 2012. Under the Company’s collaboration for North America with AbbVie, total net sales of LINZESS in the U.S., as recorded by AbbVie, are reduced by commercial costs incurred by each party, and the resulting amount is shared equally between the Company and AbbVie. Additionally, development costs are shared equally between the Company and AbbVie. AbbVie also has an exclusive license from the Company to develop and commercialize linaclotide in all countries other than China (including Hong Kong and Macau), Japan and the countries and territories of North America (the “AbbVie License Territory”). On a country-by-country and product-by-product basis in the AbbVie License Territory, AbbVie pays the Company a royalty as a percentage of net sales of products containing linaclotide as an active ingredient. In addition, AbbVie has exclusive rights to commercialize linaclotide in Canada as CONSTELLA and in Mexico as LINZESS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Astellas Pharma Inc. (“Astellas”), the Company’s partner in Japan, has an exclusive license to develop and commercialize linaclotide in Japan. In March 2017, Astellas began commercializing LINZESS for the treatment of adults with IBS-C in Japan, and in September 2018, Astellas began commercializing LINZESS for the treatment of adults with chronic constipation in Japan. In August 2019, the Company amended and restated its license agreement with Astellas. Effective in 2020, Company is no longer responsible for the supply of linaclotide active pharmaceutical ingredient (“API”) to Astellas (Note 5). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In October 2012, the Company and AstraZeneca AB (together with its affiliates) (“AstraZeneca”) entered into a collaboration agreement to co-develop and co-commercialize linaclotide in China (including Hong Kong and Macau) (the “AstraZeneca License Territory”). In September 2019, the Company amended and restated its existing collaboration agreement with AstraZeneca whereby AstraZeneca obtained the exclusive right to develop, manufacture, and commercialize products containing linaclotide in the AstraZeneca License Territory (Note 5). In November 2019, AstraZeneca began commercializing LINZESS for the treatment of adults with IBS-C in China. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>The Company and AbbVie are exploring ways to enhance the clinical profile of LINZESS by studying linaclotide in additional indications, populations and formulations to assess its potential to treat various conditions. In September 2020, based on the Phase IIIb data demonstrating efficacy and safety of LINZESS 290 mcg on the overall abdominal symptoms of bloating, pain and discomfort in adult patients with IBS-C, the U.S. FDA approved the Company’s supplemental New Drug Application to include a more comprehensive description of the effects of LINZESS in its approved label. In August 2021, the U.S. FDA approved a revised label for LINZESS based on clinical safety data that has been generated thus far in pediatric studies. The updated label modifies the boxed warning for risk of serious dehydration and contraindication against use in children to those less than two years of age. The boxed warning and contraindication previously applied to all children less than 18 years of age and less than six years of age, respectively. The safety and effectiveness of LINZESS in patients less than 18 years of age have not been established.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November 2021, the Company entered into a collaboration and license option agreement (the “COUR Collaboration Agreement”) with COUR Pharmaceutical Development Company, Inc. (“COUR”), a biotechnology company developing novel immune-modifying nanoparticles to treat autoimmune diseases. The COUR Collaboration Agreement grants the Company an option to acquire an exclusive license to research, develop, manufacture and commercialize, in the U.S., products containing CNP-104, a potential treatment for primary biliary cholangitis, a rare autoimmune disease targeting the liver.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">These and other agreements are more fully described in Note 5, <i style="font-style:italic;">Collaboration, License, and Other Agreements,</i> to these consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is also advancing IW-3300, a guanylate cyclase type C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis / bladder pain syndrome (IC/BPS) and endometriosis. In December 2021, the U.S. FDA accepted our Investigational New Drug Application, and the Phase I clinical program has commenced in the first quarter of 2022 to evaluate the safety and tolerability of IW-3300 in healthy volunteers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated in Delaware on January 5, 1998 as Microbia, Inc. On April 7, 2008, the Company changed its name to Ironwood Pharmaceuticals, Inc. To date, the Company has dedicated a majority of its activities to the research, development and commercialization of linaclotide, as well as to the research and development of its other product candidates. </p>
CY2019	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reclassifications</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain prior period financial statement items have been reclassified to conform to current period presentation. </p>
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of revenues and expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">consolidated financial statements include those related to revenue recognition; accounts receivable; useful lives of long-lived assets, impairment of long-lived assets, including goodwill; valuation procedures for right-of-use assets and operating lease liabilities; valuation procedures for the issuance and repurchase of convertible notes; balance sheet classification of convertible notes; fair value of derivatives; income taxes, including the valuation allowance for deferred tax assets; research and development expenses; contingencies and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	595200000
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	349000000.0
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	1700000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	2200000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1300000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	500000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1700000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	500000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, restricted cash, and accounts receivable. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and the Company believes that such funds are subject to minimal credit risk. The Company has adopted an investment policy which limits the amounts the Company may invest in certain types of investments, and requires all investments held by the Company to be at least AA- rated, thereby reducing credit risk exposure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable primarily consist of amounts due under the linaclotide collaboration agreement with AbbVie for North America (Note 5). The Company does not obtain collateral for its accounts receivable. The Company previously reflected amounts due from Allergan, net of amounts payable to Allergan, prior to its acquisition by AbbVie as related party accounts receivable, net. Following the acquisition of Allergan by AbbVie, the Company determined that AbbVie is not a related party to the Company (Note 16).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The percentages of revenue recognized from significant collaborative partners of the Company in the years ended December 31, 2021, 2020 and 2019 as well as the account receivable balances, net of any payables due, at December 31, 2021 and 2020 are included in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="3" style="vertical-align:bottom;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accounts</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Collaborative Partner:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">AbbVie (North America and Europe)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Astellas (Japan)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p>
CY2021	us-gaap	Lease Practical Expedients Package LeasePracticalExpedientsPackage	true
CY2021Q4	us-gaap	Lease Practical Expedient Lessor Single Lease Component LeasePracticalExpedientLessorSingleLeaseComponent	true
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	528448000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	106176000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	21505000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	162245000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	159427000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	156023000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	164418000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	160655000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	156023000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.26
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.67
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.21
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.66
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54428000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	58554000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	67087000
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	138000000.0
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	145800000
CY2021Q4	irwd	Accounts Receivable Net Of Accounts Payable Current And Noncurrent AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent	112200000
CY2020Q4	irwd	Accounts Receivable Net Of Accounts Payable Current And Noncurrent AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent	110900000
CY2021Q4	irwd	Contingent Sales Related Milestone Receivable ContingentSalesRelatedMilestoneReceivable	80000000.0
CY2021Q4	irwd	Threshold Percentage Of Collateralized Value ThresholdPercentageOfCollateralizedValue	1.02
CY2021Q4	irwd	Threshold Percentage Of Collateralized Value ThresholdPercentageOfCollateralizedValue	1.02
CY2019	irwd	Fair Value Transfer Between Measurement Levels FairValueTransferBetweenMeasurementLevels	0
CY2020	irwd	Fair Value Transfer Between Measurement Levels FairValueTransferBetweenMeasurementLevels	0
CY2021	irwd	Fair Value Transfer Between Measurement Levels FairValueTransferBetweenMeasurementLevels	0
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	31366000
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	24260000
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-18301000
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-12172000
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	13065000
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	12088000
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-11950000
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-10772000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	1115000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1316000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2520000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2530000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	16452000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	1526000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	960000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1420000
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1512000
CY2021	us-gaap	Lease Cost LeaseCost	3480000
CY2020	us-gaap	Lease Cost LeaseCost	3950000
CY2019	us-gaap	Lease Cost LeaseCost	19490000
CY2019	us-gaap	Sublease Income SubleaseIncome	300000
CY2019	irwd	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Upon Adoption Of New Accounting Standard Codification RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityUponAdoptionOfNewAccountingStandardCodification	88299000
CY2019	irwd	Adjustment To Right Of Use Asset Lease Modification AdjustmentToRightOfUseAssetLeaseModification	-40427000
CY2019	irwd	Adjustment To Right Of Use Asset Lease Termination AdjustmentToRightOfUseAssetLeaseTermination	34440000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18452000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3128000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1146000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	18598000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y3M18D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3129000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3065000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3126000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3189000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3252000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	11603000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	27364000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5753000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21611000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3127000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18484000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17203000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20734000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9628000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11805000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7575000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8929000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1500000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2300000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5600000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16653000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13413000
CY2021Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	462000
CY2020Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	10510000
CY2021Q4	irwd	Accrued Stock Repurchase Liability Current AccruedStockRepurchaseLiabilityCurrent	3009000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3442000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2563000
CY2021Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	23566000
CY2020Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	26486000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3400000
CY2021Q4	irwd	Other Accrued Liabilities Current Uninvoiced Vendor Liabilities OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities	2700000
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	300000
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	200000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2600000
CY2020Q4	irwd	Other Accrued Liabilities Current Uninvoiced Vendor Liabilities OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities	2100000
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	300000
CY2015Q2	us-gaap	Payments For Hedge Investing Activities PaymentsForHedgeInvestingActivities	21100000
CY2019Q3	us-gaap	Payments For Hedge Investing Activities PaymentsForHedgeInvestingActivities	25200000
CY2019Q3	irwd	Debt Instrument Conditional Conversion Repurchase Price Principal Percentage DebtInstrumentConditionalConversionRepurchasePricePrincipalPercentage	1
CY2019Q3	irwd	Debt Instrument Default Payment Percentage Of Principal Amount Of Notes Outstanding DebtInstrumentDefaultPaymentPercentageOfPrincipalAmountOfNotesOutstanding	0.25
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	7216000
CY2020	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	7216000
CY2019	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	7361000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1678000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1462000
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1190000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	22256000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	20800000
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	17683000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	31150000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	29478000
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	26234000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	126557000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4500000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	203750000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3000000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	201500000
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	539307000
CY2021Q4	irwd	Long Term Debt Maturities Interest Payments LongTermDebtMaturitiesInterestPayments	18608000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	61641000
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	4867000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	454191000
CY2015Q2	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	21100000
CY2019Q3	irwd	Proceeds From Partial Termination Of Convertible Note Hedges And Warrants ProceedsFromPartialTerminationOfConvertibleNoteHedgesAndWarrants	3200000
CY2021	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Class A Common Stock is entitled to one vote per share.
CY2021Q4	irwd	Common Stock Voting Rights Per Share CommonStockVotingRightsPerShare	1
CY2021Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	150000000.0
CY2021Q2	us-gaap	Stock Repurchase Program Expiration Date StockRepurchaseProgramExpirationDate	2022-12-31
CY2021	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	2400000
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	27100000
CY2021Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	122900000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.89
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.10
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22281000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31175000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31278000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22281000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31175000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31278000
CY2021	irwd	Share Based Compensation Arrangements By Share Based Payment Award Options Expiration Term ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm	P10Y
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-251367000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-81927000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-333294000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-327791000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2685000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-327800000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5500000
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	2700000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13459671
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.25
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y3M7D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5613000
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1698362
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.83
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2388515
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	13.07
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9372794
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.30
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M3D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4528000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9331488
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	12.31
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y5M26D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	4509000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8972651
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.33
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y4M17D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4385000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2700000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3500000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5100000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5503000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2685000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5503000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2685000
CY2021Q4	irwd	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	4981000
CY2020Q4	irwd	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	7498000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	16857000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	21848000
CY2021Q4	irwd	Deferred Tax Assets Collaboration Agreement DeferredTaxAssetsCollaborationAgreement	78194000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	42138000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	22861000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4517000
CY2021	irwd	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Share Based Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingShareBasedCompensationAmount	34000
CY2020	irwd	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Share Based Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingShareBasedCompensationAmount	74000
CY2019	irwd	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Share Based Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingShareBasedCompensationAmount	65000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	12554000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7565000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1902000
CY2019	irwd	Effective Income Tax Rate Reconciliation Disallowed Separation Related Costs EffectiveIncomeTaxRateReconciliationDisallowedSeparationRelatedCosts	4658000
CY2021	irwd	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	695000
CY2020	irwd	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	1718000
CY2019	irwd	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	662000
CY2021	irwd	Effective Income Tax Rate Reconciliation Meals And Entertainment EffectiveIncomeTaxRateReconciliationMealsAndEntertainment	349000
CY2020	irwd	Effective Income Tax Rate Reconciliation Meals And Entertainment EffectiveIncomeTaxRateReconciliationMealsAndEntertainment	395000
CY2019	irwd	Effective Income Tax Rate Reconciliation Meals And Entertainment EffectiveIncomeTaxRateReconciliationMealsAndEntertainment	495000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	43000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-144000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1202000
CY2021	irwd	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Windfalls IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls	-6270000
CY2020	irwd	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Windfalls IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls	-5132000
CY2019	irwd	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Windfalls IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls	-3324000
CY2021	irwd	Income Tax Reconciliation Fair Market Valuation Of Note Hedge Warrants And Convertible Note Hedges IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges	325000
CY2020	irwd	Income Tax Reconciliation Fair Market Valuation Of Note Hedge Warrants And Convertible Note Hedges IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges	1680000
CY2019	irwd	Income Tax Reconciliation Fair Market Valuation Of Note Hedge Warrants And Convertible Note Hedges IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges	-290000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	9000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	3149000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	4374000
CY2021	irwd	Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits	491000
CY2020	irwd	Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits	1991000
CY2019	irwd	Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits	3764000
CY2021	irwd	Income Tax Reconciliation Change In Enacted State And Local Tax Rates IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates	123000
CY2020	irwd	Income Tax Reconciliation Change In Enacted State And Local Tax Rates IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates	-208000
CY2019	irwd	Income Tax Reconciliation Change In Enacted State And Local Tax Rates IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates	-2563000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-390804000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-35230000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-7154000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-327791000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2685000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	165022000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	234772000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	60125000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	60607000
CY2020Q4	irwd	Deferred Tax Assets Collaboration Agreement DeferredTaxAssetsCollaborationAgreement	62629000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	51699000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5003000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	6114000
CY2021Q4	irwd	Deferred Tax Assets Convertible Senior Notes DeferredTaxAssetsConvertibleSeniorNotes	8166000
CY2020Q4	irwd	Deferred Tax Assets Convertible Senior Notes DeferredTaxAssetsConvertibleSeniorNotes	6183000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	5396000
CY2020Q4	irwd	Deferred Tax Assets Interest Expense DeferredTaxAssetsInterestExpense	3386000
CY2021Q4	irwd	Deferred Tax Assets Operating Leases DeferredTaxAssetsOperatingLeases	5971000
CY2020Q4	irwd	Deferred Tax Assets Operating Leases DeferredTaxAssetsOperatingLeases	6504000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3997000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5049000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	353712000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	414590000
CY2021Q4	irwd	Deferred Tax Liabilities Convertible Senior Notes2024 DeferredTaxLiabilitiesConvertibleSeniorNotes2024	4363000
CY2020Q4	irwd	Deferred Tax Liabilities Convertible Senior Notes2024 DeferredTaxLiabilitiesConvertibleSeniorNotes2024	5951000
CY2021Q4	irwd	Deferred Tax Liabilities Convertible Senior Notes2026 DeferredTaxLiabilitiesConvertibleSeniorNotes2026	7597000
CY2020Q4	irwd	Deferred Tax Liabilities Convertible Senior Notes2026 DeferredTaxLiabilitiesConvertibleSeniorNotes2026	9022000
CY2021Q4	irwd	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	4248000
CY2020Q4	irwd	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	4603000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	16208000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	19576000
CY2021Q4	irwd	Deferred Tax Assets Net Including Valuation Allowances DeferredTaxAssetsNetIncludingValuationAllowances	337504000
CY2020Q4	irwd	Deferred Tax Assets Net Including Valuation Allowances DeferredTaxAssetsNetIncludingValuationAllowances	395014000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4210000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	395014000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	333294000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	irwd	Deferred Tax Assets Net Including Valuation Allowances DeferredTaxAssetsNetIncludingValuationAllowances	337500000
CY2020Q4	irwd	Deferred Tax Assets Net Including Valuation Allowances DeferredTaxAssetsNetIncludingValuationAllowances	395000000.0
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-390800000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-35200000
CY2021Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	64700000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	68087000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	53099000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	38551000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	83206000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	66687000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1400000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104031000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103747000
CY2021Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	117130000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	413753000
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	43447000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	51699000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	38551000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	84606000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	68087000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	53099000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	84600000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	68100000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	53100000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	84600000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1400000
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	2900000
CY2020	irwd	Defined Contribution Plan Employer Matching Contribution Employee Contribution Percent DefinedContributionPlanEmployerMatchingContributionEmployeeContributionPercent	0.75
CY2019	irwd	Defined Contribution Plan Employer Matching Contribution Employee Contribution Percent DefinedContributionPlanEmployerMatchingContributionEmployeeContributionPercent	0.75
CY2020	irwd	Defined Contribution Plan Employer Matching Contribution Employee Contribution Maximum DefinedContributionPlanEmployerMatchingContributionEmployeeContributionMaximum	6000
CY2019	irwd	Defined Contribution Plan Employer Matching Contribution Employee Contribution Maximum DefinedContributionPlanEmployerMatchingContributionEmployeeContributionMaximum	6000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2200000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1800000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2200000
CY2020	us-gaap	Restructuring Charges RestructuringCharges	15400000
CY2019	us-gaap	Restructuring Charges RestructuringCharges	3600000
CY2020Q4	us-gaap	Restructuring Reserve RestructuringReserve	10907000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	1073000
CY2021	us-gaap	Payments For Restructuring PaymentsForRestructuring	10664000
CY2021	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-854000
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	462000
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	88845000
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	38933000
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	38576000
CY2021Q4	us-gaap	Costs And Expenses CostsAndExpenses	60538000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	181494000
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5040000
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10726000
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5499000
CY2021Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10337000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-31602000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	39926000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	391303000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	55845000
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	41374000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	528448000
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.25
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.42
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.34
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.25
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.26
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.39
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.34
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.21
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79943000
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	89432000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103468000
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	116680000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	389523000
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	66716000
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	56719000
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	57852000
CY2020Q4	us-gaap	Costs And Expenses CostsAndExpenses	65296000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	246583000
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9882000
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7509000
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9804000
CY2020Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6884000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-34079000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	3345000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	25204000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	34423000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	43204000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	106176000
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.22
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.67
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.66

Files In Submission

Name	View Source	Status
0001558370-22-001368-index-headers.html	Edgar Link	pending
0001558370-22-001368-index.html	Edgar Link	pending
0001558370-22-001368.txt	Edgar Link	pending
0001558370-22-001368-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
irwd-20211231.xsd	Edgar Link	pending
irwd-20211231x10k.htm	Edgar Link	pending
irwd-20211231x10k002.jpg	Edgar Link	pending
irwd-20211231x10k_htm.xml	Edgar Link	completed
irwd-20211231xex23d1.htm	Edgar Link	pending
irwd-20211231xex31d1.htm	Edgar Link	pending
irwd-20211231xex31d2.htm	Edgar Link	pending
irwd-20211231xex32d1.htm	Edgar Link	pending
irwd-20211231xex32d2.htm	Edgar Link	pending
irwd-20211231_cal.xml	Edgar Link	unprocessable
irwd-20211231_def.xml	Edgar Link	unprocessable
irwd-20211231_lab.xml	Edgar Link	unprocessable
irwd-20211231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R135.htm	Edgar Link	pending
R136.htm	Edgar Link	pending
R137.htm	Edgar Link	pending
R138.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd

2021 Q4 Form 10-K Financial Statement

#000155837022001368 Filed on February 18, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD IRONWOOD PHARMACEUTICALS INC Stock $irwd

2021 Q4 Form 10-K Financial Statement

#000155837022001368 Filed on February 18, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd